News

Due Diligence for Medical Products: An FDA Regulatory and Supply Chain Perspective

September 21, 2020
Arnold & Porter Webinar

In this webinar, our speakers highlight some of the most important FDA­ and supply chain-­related due diligence considerations for parties to transactions in the life sciences sector, and provide practical advice on addressing critical issues necessary to avoid downstream complications and unanticipated liabilities.

Topics

  • Issues related to developing investigational medical products
  • FDA applications
  • Compliance with FDA's Current Good Manufacturing Practice (CGMP) regulation
  • Government enforcement actions
  • Supply chain safety concerns
  • Implications of President Trump's August 2020 "Buy American" executive order
  • Role of foreign regulatory bodies

Meet the Speakers

Howard Sklamberg
Partner
Arnold & Porter
Ira Stup
Associate
Arnold & Porter
Subscribe
Subscribe Link

Email Disclaimer